← 홈

CGT

121개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 121개
CGTBiologicShanghai Unicar-Therapy Bio-med…Phase 1

chimeric antigen receptor T cell (chimeric antigen receptor T cell)

Pancreatic Cancer; CAR · FRα

#FR#CGT#Phase1#인기#세포유전치료+5
효능 ORR 67%임상시험 62상태 ACTIVE
CGTBiologicYake Biotechnology Ltd.Phase 1

chimeric antigen receptor T cell treatment (chimeric antigen receptor T cell treatment)

T Cell Lymphoma; T-cell Leukemia · FRα

#FR#CGT#Phase1#인기#세포유전치료+5
효능 ORR 80.3%임상시험 62상태 ACTIVE
CGTBiologicAbbottPhase 1

valproic acid (valproic acid)

Advanced Malignant Neoplasm; Castleman Disease · FRα

#FR#CGT#Phase1#인기#세포유전치료+5
임상시험 62상태 DISCONTINUED
CGTBiologicHebei Senlang Biotechnology Inc…Phase 2

Autologous CAR-T cells (Autologous CAR-T cells)

Leukemia; Lymphoma · FRα

#FR#CGT#Phase2#인기#세포유전치료+5
효능 ORR 80.3%임상시험 61상태 ACTIVE
CGTBiologicThomas Martin, MDPhase 1

Biospecimen Collection (Biospecimen Collection)

Multiple Myeloma; Recurrent Multiple Myeloma · FRα

#FR#CGT#Phase1#인기#세포유전치료+5
효능 ORR 11.11%임상시험 61상태 DISCONTINUED
CGTBiologicMedigene AGPhase 2

Lymphodepletion (Lymphodepletion)

Epithelial Ovarian Cancer; Gastro-esophageal Junction Cancer · FRα

#FR#CGT#Phase2#인기#세포유전치료+5
효능 0%임상시험 60상태 DISCONTINUED
CGTBiologicMarzieh EbrahimiPhase 1

Allogenic NK cells infusion (Allogenic NK cells infusion)

Neuroblastoma, Recurrent, Refractory; Neuroblastoma (NB) · FRα

#FR#CGT#Phase1#인기#세포유전치료+5
효능 ORR 5%임상시험 56상태 RECRUITING
CGTBiologicKitevedotin plus bendamustine a…Approved

axicabtagene ciloleucel (Yescarta, axi-cel)

Large B-cell Lymphoma; Lymphoma, B-Cell · FRα

#FR#CGT#Approved#인기#세포유전치료+5
효능 ORR 92%임상시험 53상태 RECRUITING
CGTBiologicHistograft Co., Ltd.operatedPreclinical

"Histograft", a bone substitute based on octacalcium phosphate (OCP, "Histograft", a bone substitute based on octacalcium phosphate, "Histograft", a bone substitute based on octacalcium phosphate (OCP) and plasmid DNA encoding VEGFA gene)

Non Union Fracture; Non-Union of Ankle Joint Without Infection · FRα

#FR#CGT#Preclinical#세포유전치료#CAR-T+5
임상시험 45상태 ACTIVE
CGTBiologicSecuraBio-deliveringPhase 3

Duvelisib (Duvelisib)

Indolent Non-Hodgkin's Lymphoma; Follicular Lymphoma · FRα

#FR#CGT#Phase3#세포유전치료#CAR-T+5
효능 ORR 82%임상시험 45상태 RECRUITING
CGTBiologicNovartisPhase 3

tisagenlecleucel (Kymriah, tisa-cel)

Acute Lymphoblastic Leukemia · FRα

#FR#CGT#Phase3#세포유전치료#CAR-T+4
효능 ORR 83.3%임상시험 45상태 DISCONTINUED
CGTBiologicOHSU Knight Cancer InstitutePhase 2

Hyper-CVAD (Hyper-CVAD)

Relapsed/Refractory; B-cell Acute Lymphocytic Leukemia · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+5
효능 ORR 89%임상시험 40상태 RECRUITING
CGTBiologiciCell Gene TherapeuticsPhase 1

CD4 CAR T cells (CD4 CAR T cells)

T Cell Lymphoma in Relapse; Refractory T-Cell Lymphoma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+5
효능 ORR 80.3%임상시험 39상태 ACTIVE
CGTBiologicSung-Soo ParkPreclinical

IMiD treatment (IMiD treatment)

Multiple Myeloma, Relapsed; Multiple Myeloma (MM) · FRα

#FR#CGT#Preclinical#세포유전치료#CAR-T+5
효능 ORR 48.3%임상시험 39상태 RECRUITING
CGTBiologicNovartis PharmaceuticalsPhase 2

CTL019 T-cells (CTL019 T-cells)

B-cell Acute Lymphoblastic Leukemia; Relapsed B-cell Acute Lymphoblastic Leukemia · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+5
효능 ORR 82.3%임상시험 37상태 ACTIVE
CGTBiologicHe HuangPhase 1

CAR-T cells chimeric antigen receptor T cells (CAR-T cells chimeric antigen receptor T cells)

Relapsed/Refractory Acute Myeloid Leukemia(AML) · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+5
효능 0%임상시험 32상태 RECRUITING
CGTBiologicPaolo Caimi, MDPhase 1

BAFF CAR-T (BAFF CAR-T)

Relapsed CLL; Refractory CLL · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 15상태 RECRUITING
CGTBiologicstaleBiohaven Pharmaceuticals, Inc.Phase 1

CIML-NK cell therapy (CIML-NK cell therapy)

Acute Myeloid Leukemia Refractory; Acute Myeloid Leukemia, in Relapse · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 12상태 RECRUITING
CGTBiologicstaleMiltenyi Biotec, Inc.Phase 1

Autologous CAR19 T lymphocytes (Autologous CAR19 T lymphocytes)

Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia; Non-Hodgkin's Lymphoma Refractory · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4
효능 ORR 77.3%임상시험 7상태 RECRUITING
CGTBiologicstaleShanghai AbelZeta Ltd.Phase 1

C-CAR-011 (C-CAR-011)

Refractory Diffuse Large B-Cell Lymphoma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 6상태 ACTIVE

1 / 7 페이지

← 이전다음 →